PPIDT00267
Drug Information
| Name | Asfotase alfa |
|---|---|
| Sequence | LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD |
| DrugBank_ID | DB09105 |
| Type | biotech |
| Indication | Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP). |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
100 MG/ML
|
| Injection, solution | Subcutaneous |
40 MG/ML
|
| Solution | Subcutaneous |
100 mg / mL
|
| Solution | Subcutaneous |
18 mg/0.45mL
|
| Solution | Subcutaneous |
28 mg/0.7mL
|
| Solution | Subcutaneous |
40 mg/1mL
|
| Solution | Subcutaneous |
40 mg / mL
|
| Solution | Subcutaneous |
80 mg/0.8mL
|
| Injection, solution | Subcutaneous |
18 mg/0.45ml
|
| Injection, solution | Subcutaneous |
28 mg/0.7ml
|
| Injection, solution | Subcutaneous |
40 mg/1.0ml
|
| Injection, solution | Subcutaneous |
80 mg/0.8ml
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| No target records. | ||||||